Ensem’s ETX-929 is candidate for KRAS mutant tumors

Ensem Therapeutics Inc. has presented data for ETX-929, a small-molecule, oral pan-KRAS inhibitor with potent ON and OFF dual-state inhibitory activity for both wild-type and mutant KRAS.